Document:

exv10w10

Exhibit 10.10

			
	 	 	 
	$1,500,000
	 	April 14, 2010

THIS SENIOR CONVERTIBLE PROMISSORY NOTE (“NOTE”) AND THE SECURITIES ISSUABLE UPON
CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY
STATE OR OTHER SECURITIES LAWS AND MAY NOT BE OFFERED, SOLD, TRANSFERRED, OR ASSIGNED EXCEPT (i)
PURSUANT TO REGISTRATIONS THEREOF UNDER SUCH LAWS, OR (ii) IN COMPLIANCE WITH APPLICABLE
SECURITIES LAWS WITHOUT SUCH REGISTRATIONS.

THIS NOTE IS BEING ISSUED PURSUANT TO A LOAN AND SECURITY AGREEMENT BETWEEN MAKER AND HOLDER DATED
AS OF APRIL 14, 2010 (THE “LOAN AGREEMENT”).

SENIOR CONVERTIBLE PROMISSORY NOTE

     Cardiovascular Systems, Inc., a Delaware corporation (the “Maker”), for value
received, promises to pay, so long as a Conversion Event has not occurred prior to April 14, 2015,
to Partners for Growth III, L.P. (“Holder”) the principal sum of One Million Five Hundred
Thousand Dollars (the “Principal Amount”) on April 14, 2015 or, if earlier, immediately
upon Holder demand after the occurrence of an Event of Default under the Loan Agreement that is
continuing (the “Maturity Date”) as provided herein. Capitalized terms used but not
defined herein are used with the meanings given to them in the Loan Agreement. This Note is one of
several Notes contemplated to be issued under the Loan Agreement, differing only as to issue date,
Principal Amount, interest rate and Conversion Price. The terms of the Loan Agreement shall govern
this Note and are incorporated by reference herein.

     1. Payments.

          (a) The interest rate payable hereunder shall be the Prime Rate from time to time, plus 2.75%,
per annum, payable monthly on the basis set forth in Section 2 of the Schedule to the Loan
Agreement. Any accrued and unpaid interest on this Note will be due and payable on the day that
all principal is due and payable, whether on the Maturity Date, by acceleration, at the time of a
Conversion Event or otherwise.

          (b) Payment shall be made in lawful tender of the United States in immediately available
funds, and shall be credited first to accrued interest then due and payable with the remainder
applied to principal. This Note may not be prepaid in whole or in part at any time prior to the
Maturity Date.

     2. Ranking. This Note and all principal, interest and other amounts, if any, payable
hereunder shall rank senior in right of payment to all other Maker Indebtedness, except as
otherwise specified in the Loan Agreement.

     3. Conversion.

 

 

          (a) This Note may be converted into that number of shares of Common Stock (rounded down to the
nearest whole share) determined by dividing the Principal Amount (excluding interest) of this Note
by $5.43 (the “Conversion Price”), subject to adjustment below, at any time upon the
election of the Holder hereof (the “Holder Conversion”) or at the election of Maker upon a “Force
Conversion, as described in Section 1(c) of the Schedule to the Loan Agreement, all in accordance
with and subject to the terms and conditions of the Loan Agreement (each a “Conversion Event”).

          (b) As soon as practicable after the occurrence of a Conversion Event, and in any event within
the time periods specified in Sections 1(b) and 1(c) of the Schedule to the Loan Agreement, Maker
at its expense will cause to be issued in the name of and delivered to Holder, a certificate or
certificates for the number of shares of Conversion Stock to which Holder shall be entitled on such
conversion. No fractional Conversion Stock shall be issued on conversion of the Note. If on
conversion of the Note a fraction of a share of Conversion Stock results, Maker will pay the cash
value of that fractional share based on the Conversion Price then in effect.

          (c) From and after the occurrence of a Conversion Event, Maker shall reserve and keep
available out of its authorized but unissued Common Stock such number of shares of Common Stock as
shall from time to time be sufficient to effect conversion of this Note and all other Notes. Maker
will not, by amendment of its Certificate of Incorporation or through any reorganization,
recapitalization, transfer of assets, consolidation, merger, dissolution, issue or sale of
securities, dividend or other distribution of cash or property, or any other voluntary action,
avoid or seek to avoid the observance or performance of any of the terms to be observed or
performed hereunder by Maker, but will at all times in good faith assist in the carrying out of all
the provisions hereof, and in the taking of all such action as may be necessary or appropriate in
order to protect the conversion rights of Holder as set forth herein against impairment.

     4. Conversion Adjustments.

     (a) Adjustments. The Conversion Price shall be subject to adjustment from time to
time in accordance with this Section 4.

     (b) Subdivisions, Combinations and Stock Dividends. If Maker shall at any time
subdivide by split-up or otherwise, its outstanding Common Stock into a greater number of shares,
or issue additional Common Stock as a dividend, bonus issue or otherwise with respect to any Common
Stock, the Conversion Price in effect immediately prior to such subdivision or share dividend or
bonus issue shall be proportionately reduced. Conversely, in case the outstanding Common Stock of
Maker shall be combined into a smaller number of shares, the Conversion Price in effect immediately
prior to such combination shall be proportionately increased.

     (c) Reclassification, Exchange, Substitutions, Etc. Upon any reclassification,
exchange, substitution, or other event that results in a change of the number and/or class of the
securities issuable upon conversion of this Note, Holder shall be entitled to receive, upon
conversion of this Note, the number and kind of securities and property that Holder would have
received in exchange for the securities that would have been issued on conversion if this Note had
been converted immediately before such reclassification, exchange, substitution, or other event.

 

 

Maker or its successor shall promptly issue to Holder a certificate setting forth the number
and kind of such new securities or other property issuable upon exchange or exercise of this Note
as a result of such reclassification, exchange, substitution or other event that results in a
change of the number and/or class of securities issuable upon exchange or exercise of this Note.
The certificate shall provide for adjustments (as determined in good faith by Maker’s Board of
Directors) which shall be as nearly equivalent as may be practicable to the adjustments provided
for in this Article 4 including, without limitation, adjustments to the Conversion Price. The
provisions of this Section 4(b) shall similarly apply to successive reclassifications, exchanges,
substitutions, or other similar events.

     (d) Notices of Record Date, Etc. In the event that Maker shall:

     (1) declare or propose to declare any dividend upon its Common Stock, whether payable in cash,
property, stock or other securities and whether or not a regular cash dividend, or

     (2) offer for sale any additional shares of any class or series of Maker’s stock or
securities exchangeable for or convertible into such stock in any transaction that would give rise
(regardless of waivers thereof) to pre-emptive rights of any class or series of stockholders, or

     (3) effect or approve any reclassification, exchange, substitution or recapitalization of the
capital stock of Maker, including any subdivision or combination of its outstanding capital stock,
or consolidation or merger of Maker with, or sale of all or substantially all of its assets to,
another corporation, or to liquidate, dissolve or wind up (including an assignment for the benefit
of creditors), or

     (4) offer holders of registration rights the opportunity to participate in any public
offering of Maker’s securities,

then, in connection with such event, Maker shall give to Holder:

     (i) at least ten (10) days prior written notice of the date on which the books of Maker shall
close or a record shall be taken for such a dividend or offer in respect of the matters referred to
in (1) or (2) above, or for determining rights to vote in respect of the matters referred to in (3)
above; and

     (ii) in the case of the matters referred to in (3) above, at least ten (10) days prior written
notice of the date when the same shall take place. Such notice in accordance with the foregoing
clause (1) shall also specify, in the case of any such dividend, the date on which the holders of
capital stock shall be entitled thereto and the terms of such dividend, and such notice in
accordance with clause (2) shall also specify the date on which the holders of capital stock shall
be entitled to exchange their capital stock for securities or other property deliverable upon such
reorganization, reclassification, exchange, substitution, consolidation, merger or sale, as the
case may be, and the terms of such exchange. Each such written notice shall be given by first class
mail, postage prepaid, addressed to the holder of this Note at the address of Holder; and

 

 

     (iii) in the case of the matter referred to in (4) above, the same notice as is given or
required to be given to the holders of such registration rights.

     (e) Adjustment by Board of Directors. If any event occurs as to which, in the opinion
of the Board of Directors of Maker, the provisions of this Section 4 are not strictly applicable or
if strictly applicable would not fairly protect the rights of the Holder in accordance with the
essential intent and principles of such provisions, then the Board of Directors shall make an
adjustment in the application of such provisions, in accordance with such essential intent and
principles, so as to protect such rights, but in no event shall any adjustment have the effect of
increasing the Conversion Price as otherwise determined pursuant to any of the provisions of this
Section 4, except in the case of a combination of shares of a type contemplated in Section 4(b) and
then in no event to an amount larger than the Conversion Price as adjusted pursuant to Section
4(b).

     (f) Officers’ Statement as to Adjustments. Whenever the Conversion Price is required
to be adjusted as provided in Section 4, Maker shall forthwith file at each the Company’s principal
office with a copy to the Holder notice parties set forth in Section 7 hereof a statement, signed
by the Chief Executive Officer or Chief Financial Officer of Maker, showing in reasonable detail
the facts requiring such adjustment and the Conversion Price that will be effective after such
adjustment; provided, however, such statement shall not be required to the extent the information
requested in this Section 4.6 is available through Maker’s current reports filed with the
Securities and Exchange Commission. If at any time the information described in this Section 4.6 is
readily available through Maker’s reports filed with the Securities and Exchange Commission, Maker
shall not be required to provide a separate notice of adjustment to the Holder; provided, however,
if such information is not readily available through Maker’s current reports filed with the
Securities Exchange Commission and made public, Maker shall cause a notice setting forth any such
adjustments to be sent by mail, first class, postage prepaid, to the record Holder of this Note at
its notice address(es) appearing in Section 7.

     (g) Issue of Securities other than Common Stock. In the event that at any time, as a
result of any adjustment made pursuant to Section 4, the Holder thereafter shall become entitled to
receive any securities of Maker, other than Common Stock, thereafter the number of such other
shares so receivable upon exchange of this Note shall be subject to adjustment from time to time in
a manner and on terms as nearly equivalent as practicable to the provisions with respect to the
Common Stock contained in Section 4.

     5. Events of Default. An Event of Default shall be deemed to have occurred under this
Note if an Event of Default has occurred under the Loan Agreement or any other Loan Document (each,
an “Event of Default”)

     6. No Offset Rights. Maker may not offset any amounts due or claimed to be due from
Holder to Maker against amounts due to Holder under this Note.

     7. Series of Notes. This Note is one of a series of Notes of like tenor issued in an
original aggregate principal amount of up to the Credit Limit under the Loan Agreement (plus such
additional principal amounts of Notes that may be permitted to be issued as a result of Conversion
Events and subsequent issue of Notes in accordance with the Loan Agreement.

 

 

     8. Costs and Expenses. Maker promises to pay all reasonable costs and expenses
incurred, including reasonable attorneys’ fees, incurred by Holder in connection with the
enforcement of, or collection of any amounts due under, this Note. Maker hereby waives notice of
default, presentment or demand for payment, protest or notice of nonpayment or dishonor and all
other notices or demands relative to this instrument, except for notices to which Maker is
expressly entitled under this Note.

     9. Successors and Assigns. This Note shall be binding upon, and shall inure to the
benefit of, Maker and Holder and their respective successors and assigns; provided, however, that
neither this Note nor any of the rights, interests or obligations hereunder may be assigned, by
operation of law or otherwise, in whole or in part, by Maker without the prior written consent of
Holder.

     10. Modifications and Amendments; Reissuance of Note. This Note may only be modified,
amended, or terminated (other than by payment in full) by an agreement in writing signed by Maker
and Holder. No waiver of any term, covenant or provision of this Note shall be effective unless
given in writing by Holder. Upon receipt of evidence reasonably satisfactory to Maker of the loss,
theft, destruction, or mutilation of this Note and of an unsecured agreement of indemnity
reasonably satisfactory to Maker, and upon surrender or cancellation of this Note, if mutilated,
Maker will make and deliver a new Note of like tenor in lieu of such lost, stolen, destroyed, or
mutilated Note.

     11. Remedies Cumulative. Each and every right, power and remedy herein given to
Holder, or otherwise existing, shall be cumulative and not exclusive and be in addition to all
other rights, powers and remedies now or hereafter granted (including, without limitation, other
rights of set-off under applicable law) or otherwise existing. Each and every right, power and
remedy whether specifically herein given or otherwise existing may be exercised from time to time
and as often and in such order as may be deemed expedient by Holder.

     12. Notices. All notices or other communications required or permitted hereunder
shall be in writing and shall be deemed effectively given in the manner set forth in the Loan
Agreement, addressed as follows:

     if to Holder, at

Partners for Growth III, L.P.

180 Pacific Avenue

San Francisco, California 94111

Attention: Chief Financial Officer

Fax: (415) 781-0510

     with a copy (not constituting notice) to

Greenspan Law Office

Attn: Benjamin Greenspan, Esq.

620 Laguna Road

Mill Valley, CA 94941

 

 

Fax: (415) 738-5371

Email: ben@greenspan-law.com

or

     if to Maker, at

Cardiovascular Systems, Inc.

651 Campus Drive

St. Paul, MN 55112

Attn: Larry Betterley

Fax: (651) 259-1696

Email: lbetterley@csi360.com

     with a copy (not constituting notice) to:

Fredrikson & Byron

200 6th Street South

Minneapolis, MN 55402

Attn: Bert Ranum

Fax: (612) 492-7077

Email: rranum@fredlaw.com

or at such other address and facsimile number as Holder shall have furnished to Maker in accordance
with this Section 12.

     13. Waiver. Holder shall not by any act (except by a written instrument in accordance
with Section 10 hereof), delay, indulgence, omission or otherwise be deemed to have waived any
right or remedy hereunder or to have acquiesced in any default or Event of Default or in any breach
of any of the terms and conditions hereof. No failure to exercise, nor any delay in exercising, on
the part of Holder, any right, power or privilege hereunder shall operate as a waiver thereof. No
single or partial exercise of any right, power or privilege hereunder shall preclude any other or
further exercise thereof or the exercise of any other right, power or privilege. A waiver by
Holder of any right or remedy hereunder on any one occasion shall not be construed as a bar to any
right or remedy which Holder would otherwise have on any future occasion. The rights and remedies
herein provided are cumulative, may be exercised singly or concurrently and are not exclusive of
any rights or remedies provided by law.

     14. Miscellaneous; Interpretation. Section 3.16, Section 8 and Exhibit D of the Loan
Agreement are expressly incorporated by reference herein. In the event of any direct conflict
between the terms of this Note and the terms of the Loan Agreement or any other Loan Document
referenced herein, except as to (i) the issue date of this Note, (ii) the Principal Amount of this
Note, (iii) the interest rate applicable to this Note (due to its determination as of the issue
date of a Note in accordance with Section 2 of the Schedule to the Loan Agreement, and (iv) the
Conversion Price of this Note (due to its determination as of the issue date of a Note under
Sections 1(b) and 1(c), as applicable, of the Schedule to the Loan Agreement), the terms of the
Loan Agreement and such other Loan Document shall control.

 

 

     IN WITNESS WHEREOF, Maker has caused this Note to be signed on the date first set forth above.

	 	 	 	 	 
	MAKER:	 CARDIOVASCULAR SYSTEMS, INC.

 	 
	 	/s/ Laurence L. Betterley
 	 
	 	Name:  	Laurence L. Betterley 	 
	 	Title:  	CFO 	 
	 

ACKNOWLEDGED AND AGREED

	 	 	 	 	 
	HOLDER:	 PARTNERS FOR GROWTH III, L.P.

 	 
	 	By 	 /s/ Lorraine Nield
	 
	 	 	Name: Lorraine Nield 	 
	 	 	Title: Manager, Partners for Growth III, LLC

Its General Partnerexv10w11

Exhibit 10.11

WARRANT

THIS WARRANT (“WARRANT”) WAS SOLD IN A PRIVATE TRANSACTION,
WITHOUT REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS
AMENDED (THE “SECURITIES ACT”) OR THE SECURITIES LAWS OF ANY
STATE, AND MAY BE OFFERED OR SOLD ONLY IF REGISTERED UNDER THE
SECURITIES ACT AND SUCH LAWS OR IF AN EXEMPTION FROM
REGISTRATION UNDER THE SECURITIES ACT AND SUCH LAWS IS
AVAILABLE.

	 	 	 

	Company:

	 	Cardiovascular Systems, Inc., a Delaware corporation
	Number of Shares:

	 	 147,330
	Class of Shares:

	 	Common Stock, $0.001 par value per share
	Exchange Price:

	 	 $5.43 per share
	Issue Date:

	 	April 14, 2010
	Expiration Date:

	 	April 14, 2015

     The term “Holder” shall initially refer to Partners for Growth III, L.P., a Delaware limited
partnership, which is the initial holder of this Warrant and shall further refer to any subsequent
permitted holder of this Warrant from time to time.

     The Holder is subject to certain restrictions as set forth in the Agreement.

     The Company does hereby certify and agree that, for the sum of $3,007.76 paid to Holder on the date
hereof, which the parties agree is fair consideration for this Warrant, Holder, or its permitted
successors and assigns, hereby is entitled to exchange this Warrant in Cardiovascular Systems, Inc.
(the “Company”) for One Hundred Forty-Seven Thousand Three Hundred Thirty (147,330) duly
authorized, validly issued, fully paid and non-assessable shares of its Common Stock, $0.001 par
value each, upon the terms and subject to the provisions of this Warrant. The shares of Common
Stock issuable upon exchange of this Warrant are referred to herein as the “Warrant Stock,” and the
Warrant and the Warrant Stock are sometimes together referred to as the “Securities.” Capitalized
terms used but not defined in this Warrant have their meanings as set forth in that certain Loan
and Security Agreement of even date herewith between the Company and Holder (the “Loan Agreement”).

Section 1 Term, Price and Exchange of Warrant.

     1.1 Term of Warrant. This Warrant shall be exchangeable for a period of five
(5) years from the Issue Date (hereinafter referred to as the “Expiration Date”).

     1.2 Exchange Price. The price per share at which the Warrant Stock is issuable upon
exchange of this Warrant shall be $5.43, subject to Section 1.3 (a) hereof and subject to
adjustment from time to time as set forth herein (the “Exchange Price”).

 

 

1.3 Exercise of Warrant; Exchange of Warrant.

          (a) This Warrant may be exercised as to Vested Shares only (as such term is defined in Section
1.7), in whole or in part, upon surrender to the Company at its then principal offices in the
United States of this Warrant to be exchanged, together with the form of election to exchange or
exercise attached hereto as Exhibit A duly completed and executed, and upon payment to the Company
of the Exercise Price for the number of shares of Warrant Stock in respect of which this Warrant is
then being exercised (an “Exercise”). In whole or in part in lieu of an Exercise, Holder may
exchange this Warrant as set forth in the remainder of this Section 1.3 (an “Exchange”).

          (b) Upon an Exchange, the Holder shall receive Warrant Stock such that, without the payment of any
funds, the Holder shall surrender this Warrant in exchange for the number of shares of Warrant
Stock equal to “X” (as defined below), computed using the following formula:

                                    Y * (A-B)    

X =

                                 A

Where

X   =   the number of shares of Warrant Stock to be issued to Holder

Y   =   the number of shares of Warrant Stock to be exchanged under this Warrant

A   =   the Fair Market Value of one share of Warrant Stock

B   =   the Exchange Price (as adjusted to the date of such Calculations)

*   =   multiplied by

          (c) For purposes of this Warrant, the “Fair Market Value” of one share of Warrant Stock shall be
(i) if the Company’s common stock (the “Common Stock”) is or becomes listed on a national stock
exchange or is quoted on the Nasdaq Global Select Market or Nasdaq Global Market, the highest
closing sale price reported on such exchange or market during the trading day on which Holder
delivers its Election of Exchange to the Company, or (ii) if the Common Stock is traded
over-the-counter, the highest closing bid price reported for the Common Stock during the trading
day on which Holder delivers its Election of Exchange to the Company, and if there has been no such
reported bid price for such day,
the next prior day(s) until the first such reported bid price. If the Common Stock is not traded as
contemplated in clauses (i) or (ii), above, the Fair Market Value of the Company’s Warrant Stock
shall be the price per share which the Company could obtain from a willing buyer for shares of
Common Stock sold by the Company from its authorized but unissued shares, as the Board of Directors
of the Company (“Board”) shall determine in its reasonable good faith judgment, but in no event
less than the price at which qualified employee stock options issued at such time are exercisable.
In the event that Holder elects to convert the Warrant Stock through

2

 

Exchange in connection with a transaction in which the Warrant Stock is converted into or exchanged
for another security, Holder may effect a Exchange directly into such other security.

          (d) Upon surrender of this Warrant, and the duly completed and executed form of election to
exchange or exercise, and payment of the Exchange Price or conversion of this Warrant through
Exchange, the Company shall issue and deliver within 3 business days to the Holder or such other
person as the Holder may designate in writing a certificate or certificates for the number of
shares of Warrant Stock so purchased upon the Exchange or exercise of this Warrant. Such
certificate or certificates shall be deemed to have been issued and any person so designated to be
named therein shall be deemed to have become a holder of record of such Warrant Stock as of the
date of the surrender of this Warrant, and the duly completed and executed form of election to
exchange or exercise, and payment of the Exchange Price or conversion of this Warrant through
Exchange; provided, that if the date of surrender of this Warrant and payment of the Exchange Price
is not a business day, the certificates for the Warrant Stock shall be deemed to have been issued
as of the next business day (whether before or after the Expiration Date). If this Warrant is
exchanged or exercised in part, a new warrant of the same tenor and for the number of shares of
Warrant Stock not exchanged or exercised shall be executed by the Company.

     1.4 Fractional Interests. The Company shall not be required to issue fractions of shares of
Warrant Stock upon the exchange of this Warrant. If any fraction of a share of Common Stock would
be issuable upon the exchange of this Warrant (or any portion thereof), the Company shall purchase
such fraction for an amount in cash equal to the same fraction of the last reported sale price of
the Common Stock on the NASDAQ Global Select Market or Nasdaq Global Market or any other national
securities exchange or market on which the Common Stock is then listed or traded.

     1.5 Automatic Conversion upon Expiration. In the event that, upon the Expiration Date, the
Fair Market Value of one share of Common Stock (or other security issuable upon the exchange
hereof) as determined in accordance with Section 1.3(c) is greater than the Exchange Price in
effect on such date, then this Warrant shall automatically be deemed on and as of such date to be
converted pursuant to Section 1.3 as to all Warrant Stock (or such other securities) for which it
shall not previously have been exchanged or converted, and the Company shall promptly deliver a
certificate representing the Warrant Stock (or such other securities) issued upon such conversion
to the Holder.

     1.6 Treatment of Warrant Upon Acquisition of Company.

          (a) “Acquisition”. For the purpose of this Warrant, “Acquisition” means any sale
or other disposition of all or substantially all of the assets of the Company in whatever
form, or any reorganization, consolidation, or merger of the Company (whether in a single
transaction or multiple related transactions) where the holders
of the Company’s securities before the transaction beneficially own less than 50% of the
outstanding voting securities of the surviving entity after the transaction(s).

3

 

          (b) Treatment of Warrant at Acquisition. Upon the closing of any Acquisition, the successor
entity (if applicable in such Acquisition) shall, as condition to such Acquisition, either: (i)
assume the obligations of this Warrant, and this Warrant shall be exercisable for the same
securities as would be payable for the Warrant Stock issuable upon exchange of the unexchanged
portion of this Warrant as if such Warrant Stock were outstanding on the record date for the
Acquisition (and the Warrant Price and/or number of shares of Warrant Stock shall be adjusted
accordingly) or (ii) purchase this Warrant at its “Fair Value” (as such term is defined herein).

          (c) Purchase at Fair Value.

          For purposes of this Warrant, “Fair Value” shall mean that value determined by the parties using a
Black-Scholes Option-Pricing Model (the “Black-Scholes Calculation”) with the following assumptions:
(A) a risk-free interest rate equal to the risk-free interest rate at the time of the closing of
the Acquisition (or as close thereto as practicable), (B) a contractual life of the Warrant equal
to the remaining term of this Warrant as of the date of the Acquisition, (C) an annual dividend
yield equal to dividends declared on the underlying Common Stock during the term of this Warrant
(calculated on an annual basis), and (D) a volatility factor of the expected market price of the
Company’s Common Stock comprised of: (1) if the Company is publicly traded on a national securities
exchange or is quoted on the Nasdaq Global Select Market or Nasdaq Global Market, its volatility
over the one year period prior to the Acquisition, (2) if the Company is a non-public company, the
volatility, over the one year period prior to the Acquisition, of an average of publicly-traded
companies in the same or similar industry to the Company with such companies having similar
revenues. The purchase price determined in accordance with the above shall be paid upon the initial
closing of the Acquisition and shall not be subject to any post-Acquisition closing contingencies
or adjustments; provided, however, the parties may take such post-Acquisition closing contingencies
or adjustments into account in determining the purchase price, and if the parties take any
post-Acquisition closing contingencies or adjustments into account, then upon the partial or
complete removal of those post-Acquisition closing contingencies or adjustments, a new
Black-Scholes Calculation would be made using all of the same inputs except for the value of the
Company’s shares (as determined under subclause (D)), and the increased value of such shares
(including, but not limited to any earn-out or escrowed consideration) would be paid in full to
Holder immediately after those post-Acquisition closing contingencies or adjustments can be
determined or achieved.

     1.7 Vesting. This Warrant shall vest with respect to fifty percent (50%) of the Warrant
Stock on the Issue Date (the “Initial Vesting”). The remaining Warrant Stock shall vest based upon
the extent to which the Company draws Loans under the Loan Agreement, as follows. Subject to the
terms and conditions of the Loan Agreement, after a mandatory Company borrowing as of the Closing
of the Loan, the Company may borrow up to the difference between the amount of such mandatory
borrowing at Closing and $4,000,000 (the “Availability Amount”) during the one-year period from
such Loan Closing date (such period being defined in the Loan Agreement as the “Availability
Period”). The Warrant Stock unvested after the Initial Vesting shall vest pro rata according to the percentage of
the Availability Amount that is drawn by the Company,

4

 

with such vesting to occur on the date of any such draw (up to the Credit Limit). At the expiry of
the Availability Period, Holder’s rights under this Warrant to all unvested Warrant Stock shall
terminate and expire. For example only, if the Company borrows $1,500,000 at the Closing of the
Loan and if 6 months thereafter, the Company borrows an additional $1,250,000 under the Loan
Agreement (resulting, for reference only, in $2,750,000 in aggregate principal borrowings by the
Company and $1,250,000 in remaining credit available within the Credit Limit under the Loan
Agreement), then an additional 50% of the remaining unvested Warrant Stock would immediately vest
[$1,250,000 borrowed / $2,500,000 remaining credit = 50%]. If 3 days before the one-year
anniversary of the Loan Agreement the Company borrowed an additional $500,000, then an additional
20% of Warrant Stock would vest (i.e., 70% in the aggregate of the Warrant Stock remaining unvested
after the Initial Vesting would then be vested). If there were no further borrowings within the
Availability Period, Holders rights in respect of the remaining unvested Warrant Stock would
terminate.

     Section 2. Exchange and Transfer of Warrant.

          (a) This Warrant may be transferred, in whole or in part, without restriction, subject to (i)
Holder’s compliance with applicable securities laws and delivery of an opinion of competent counsel
as to the same, if so requested by the Company, and (ii) the transferee holder of the new Warrant
assuming in writing the obligations of the Holder set forth in this Warrant and the Agreement.
Notwithstanding and without complying with the foregoing requirements, Holder may at any time
transfer this Warrant in part to SVB Financial Group and/or PFG Equity Investors, LLC. By its
acceptance of this Warrant, each such specified transferee will be deemed to have made to the
Company each of the representations and warranties set forth in Section 7 hereof and agrees to be
bound by all of the terms and conditions of this Warrant as if the original Holder hereof. A
transfer may be registered with the Company by submission to it of this Warrant, together with the
annexed Assignment Form attached hereto as Exhibit B duly completed and executed. After the
Company’s receipt of this Warrant and the Assignment Form so completed and executed, the Company
will issue and deliver to the transferee a new warrant (representing the portion of this Warrant so
transferred) at the same Exchange Price per share and otherwise having the same terms and
provisions as this Warrant, which the Company will register in the new holder’s name. In the event
of a partial transfer of this Warrant, the Company shall concurrently issue and deliver to the
transferring holder a new warrant that entitles the transferring holder to purchase the balance of
this Warrant not so transferred and that otherwise is upon the same terms and conditions as this
Warrant. Upon the due delivery of this Warrant for transfer, the transferee holder shall be deemed
for all purposes to have become the holder of the new warrant issued for the portion of this
Warrant so transferred, effective immediately prior to the close of business on the date of such
delivery, irrespective of the date of actual delivery of the new warrant representing the portion
of this Warrant so transferred.

          (b) In the event of the loss, theft or destruction of this Warrant, the Company shall execute and
deliver an identical new warrant to the Holder in substitution therefor upon the Company’s receipt
of (i) evidence reasonably satisfactory to the Company of such event and (ii) if requested by the
Company, an indemnity agreement

5

 

reasonably satisfactory in form and substance to the Company. In the event of the mutilation of or
other damage to the Warrant, the Company shall execute and deliver an identical new warrant to the
Holder in substitution therefor upon the Company’s receipt of the mutilated or damaged warrant.

          (c) The Company shall pay all reasonable costs and expenses incurred in connection with
the exchange, exercise, transfer or replacement of this Warrant, including, without
limitation, the costs of preparation, execution and delivery of a new warrant and of share
certificates representing all Warrant Stock.

Section 3. Certain Covenants.

          (a) The Company shall at all times reserve for issuance and keep available out of its authorized
and unissued Common Stock, solely for the purpose of providing for the exchange of this Warrant,
such number of shares of Common Stock as shall from time to time be sufficient therefor.

          (b) The Company will not, by amendment or restatement of its Certificate of Incorporation or Bylaws
or through reorganization, consolidation, merger, amalgamation, sale of assets or otherwise, avoid
or seek to avoid the observance or performance of any of the terms of this Warrant. Without
limiting the foregoing, the Company (i) will not increase the par value of any Warrant Stock
receivable upon the exchange of this Warrant above the amount payable therefor upon such exchange
and (ii) will take all such action as may be necessary or appropriate in order that the Company may
validly and legally issue fully paid and nonassessable shares upon the exchange or exercise of this
Warrant.

          (c) So long as Holder holds this Warrant, the Company shall deliver to Holder such reports as it
provides to its stockholders generally, as and when delivered to such stockholders. Notwithstanding
the foregoing, the Company shall provide Holder quarterly and annual financial statements upon
request, if such statements are not publicly available. The parties shall not treat the Warrant or
the Warrant Stock as being granted or issued as property transferred in connection with the
performance of services or otherwise as compensation for services rendered.

Section 4. Adjustments to Exchange Price and Number of Shares of Warrant Stock.

     4.1 Adjustments. The Exchange Price shall be subject to adjustment from time to time in
accordance with this Section 4. Upon each adjustment of the Exchange Price pursuant to this Section
4, the Holder shall thereafter be entitled to acquire upon exchange, at the Exchange Price
resulting from such adjustment, the number of shares of Common Stock of the Company obtainable by
multiplying the Exchange Price in effect immediately prior to such adjustment by the number of
shares of Common Stock acquirable immediately prior to such adjustment and dividing the product
thereof by the new Exchange Price resulting from such adjustment.

6

 

     4.2 Subdivisions, Combinations and Stock Dividends. If the Company shall at any time
subdivide by split-up or otherwise, its outstanding Common Stock into a greater number of shares,
or issue additional Common Stock as a dividend, bonus issue or otherwise with respect to any Common
Stock, the Exchange Price in effect immediately prior to such subdivision or share dividend or
bonus issue shall be proportionately reduced and the number of shares acquirable upon exchange
hereunder shall be proportionately increased. Conversely, in case the outstanding Common Stock of
the Company shall be combined into a smaller number of shares, the Exchange Price in effect
immediately prior to such combination shall be proportionately increased.

     4.3
Reclassification, Exchange, Substitutions, Etc. Upon any reclassification, exchange,
substitution, or other event that results in a change of the number and/or class of the securities
issuable upon exchange or exercise of this Warrant, Holder shall be entitled to receive an amended
warrant for the number and kind of securities and property that Holder would have received for the
Warrant Stock if this Warrant had been exercised immediately before such reclassification,
exchange, substitution, or other event. The Company or its successor shall promptly issue to Holder
an amendment to this Warrant setting forth the number and kind of such new securities or other
property issuable upon exchange or exercise of this Warrant as a result of such reclassification,
exchange, substitution or other event that results in a change of the number and/or class of
securities issuable upon exchange or exercise of this Warrant. The amendment to this Warrant shall
provide for adjustments (as determined in good faith by the Company’s Board of Directors) which
shall be as nearly equivalent as may be practicable to the adjustments provided for in this Article
4 including, without limitation, adjustments to the Warrant Price and to the number of securities
or property issuable upon exchange of the new Warrant. The provisions of this Section 4.3 shall
similarly apply to successive reclassifications, exchanges, substitutions, or other similar events.

     4.4. Notices of Record Date, Etc. In the event that the Company shall:

          (1) declare or propose to declare any dividend upon its Common Stock, whether payable in cash,
property, stock or other securities and whether or not a regular cash dividend, or

          (2) offer for sale any additional shares of any class or series of the Company’s stock or
securities exchangeable for or convertible into such stock in any transaction that would give rise
(regardless of waivers thereof) to pre-emptive rights of any class or series of stockholders, or

          (3) effect or approve any reclassification, exchange, substitution or recapitalization of the
capital stock of the Company, including any subdivision or combination of its outstanding capital
stock, or consolidation or merger of the Company with, or sale of all or substantially all of its
assets to, another corporation, or to liquidate, dissolve or wind up (including an assignment for
the benefit of creditors), or

7

 

          (4) offer holders of registration rights the opportunity to participate in any public offering of
the Company’s securities,

then,
in connection with such event, the Company shall give to Holder:

     (i) at least ten (10) days prior written notice of the date on which the books of the
Company shall close or a record shall be taken for such a dividend or offer in respect of
the matters referred to in (1) or (2) above, or for determining rights to vote in respect
of the matters referred to in (3) above; and

     (ii) in the case of the matters referred to in (3) above, at least ten (10) days prior
written notice of the date when the same shall take place. Such notice in accordance with
the foregoing clause (1) shall also specify, in the case of any such dividend, the date
on which the holders of capital stock shall be entitled thereto and the terms of such
dividend, and such notice in accordance with clause (2) shall also specify the date on
which the holders of capital stock shall be entitled to exchange their capital stock for
securities or other property deliverable upon such reorganization, reclassification,
exchange, substitution, consolidation, merger or sale, as the case may be, and the terms
of such exchange. Each such written notice shall be given by first class mail, postage
prepaid, addressed to the holder of this Warrant at the address of Holder; and

     (iii) in the case of the matter referred to in (4) above, the same notice as is given or required
to be given to the holders of such registration rights.

     4.5 Adjustment by Board of Directors. If any event occurs as to which, in the opinion of
the Board of Directors of the Company, the provisions of this Section 4 are not strictly applicable
or if strictly applicable would not fairly protect the rights of the Holder in accordance with the
essential intent and principles of such provisions, then the Board of Directors shall make an
adjustment in the application of such provisions, in accordance with such essential intent and
principles, so as to protect such rights, but in no event shall any adjustment have the effect of
increasing the Exchange Price as otherwise determined pursuant to any of the provisions of this
Section 4, except in the case of a combination of shares of a type contemplated in Section 4.2 and
then in no event to an amount larger than the Exchange Price as adjusted pursuant to Section 4.2.

     4.6 Officers’ Statement as to Adjustments. Whenever the Exchange Price and/or number of
shares of Warrant Stock subject to the Warrant is required to be adjusted as provided in Section 4,
the Company shall forthwith file at its principal office with a copy to the Holder notice parties
set forth in Section 7 hereof a statement, signed by the Chief Executive Officer or Chief Financial
Officer of the Company, showing in reasonable detail the facts requiring such adjustment, the
Exchange Price and number of issuable shares that will be effective after such adjustment;
provided, however, such statement shall not be required to the extent the information requested in
this Section 4.6 is available through the Company’s current reports filed with the Securities and Exchange Commission.
If at any time the information described in this Section 4.6 is readily available through the
Company’s reports filed with the Securities and Exchange

8

 

Commission, the Company shall not be required to provide a separate notice of adjustment to the
Holder; provided, however, if such information is not readily available through the Company’s
current reports filed with the Securities Exchange Commission and made public, the Company shall
cause a notice setting forth any such adjustments to be sent by mail, first class, postage prepaid,
to the record Holder of this Warrant at its notice address(es) appearing in Section 7.

     4.7 Issue of Securities other than Common Stock. In the event that at any time, as a result
of any adjustment made pursuant to Section 4, the Holder thereafter shall become entitled to
receive any securities of the Company, other than Common Stock, thereafter the number of such other
shares so receivable upon exchange of this Warrant shall be subject to adjustment from time to time
in a manner and on terms as nearly equivalent as practicable to the provisions with respect to the
Common Stock contained in Section 4.

Section 5. Rights and Obligations of the Warrant Holder.

     Except as otherwise specified in this Warrant, this Warrant shall not entitle the Holder to any
rights of a holder of Common Stock in the Company until such time as this Warrant is exchanged or
exercised. Subject to the Company’s ability to secure the requisite consents specified in Section
6.13, the Company hereby grants the following registration rights to Holder. If during the term of
this Warrant the Company proposes to file a registration statement under the Securities Act with
respect to an offering for its own account of any class of its equity securities (other than a
registration statement on Form S-8 (or any successor form) or any other registration statement
relating solely to employee benefit plans or filed in connection with an exchange offer, a
transaction to which Rule 145 (or any successor provision) under the Securities Act applies or an
offering of securities solely to the Company’s existing shareholders), then the Company shall in
each case give written notice of such proposed filing to Holder as soon as practicable (but no
later than 20 business days) before the anticipated filing date, and such notice shall offer Holder
the opportunity to register such number of shares of Warrant Stock as Holder may request. Holder
shall advise the Company in writing within 10 business days after the date on which the Company’s
notice is so given, setting forth the number of shares of Warrant Stock for which registration is
requested. If the Company’s offering is to be an underwritten offering, the Company shall, subject
to the further provisions of this Agreement, use its reasonable best efforts to cause the managing
underwriter or underwriters to permit the Holders of the Warrant Stock requested to be included in
the registration for such offering to include such Warrant Stock in such offering on the same terms
and conditions as any similar securities of the Company included therein, subject to Holder’s
execution of an underwriting agreement with the managing underwriter or underwriters selected by
the Company in the same manner as other holders participating in the registration. In connection
with any such offering, the Company will (i) include only such information relating to the Holder
and the sale of Holder’s securities as Holder shall specifically permit and (ii) indemnify the
Holder against liabilities, losses and damages that Holder may incur in connection with

9

 

the offering, including those relating to the applicable securities laws, and any breach by the
Company of this Warrant.

Section 6. Representations, Warranties and Covenants of the Company. The Company represents and
warrants to, and covenants with, Holder that:

     6.1 Corporate Power: Authorization. The Company has all requisite corporate power and has
taken all requisite corporate action to execute and deliver this Warrant, to sell and issue the
Warrant and Warrant Stock and to carry out and perform all of its obligations hereunder. This
Warrant has been duly authorized, executed and delivered on behalf of the Company and constitutes
the valid and binding agreement of the Company, enforceable in accordance with its terms, except
(i) as limited by applicable bankruptcy, insolvency, reorganization or similar laws relating to or
affecting the enforcement of creditors’ rights generally and (ii) as limited by equitable
principles generally. The person executing this Warrant is a duly authorized officer of the Company
with all necessary legal authority to bind the Company generally and with the specific legal
authority to cause the Company to execute and deliver this Warrant.

     6.2 Validity of Securities. This Warrant, when sold against the consideration therefor as
provided therein, will be validly authorized, issued and fully paid. The issuance and delivery of
the Warrant is not subject to preemptive or any similar rights of the stockholders of the Company
(which have not been duly waived) or any liens or encumbrances except for restrictions on transfer
provided for herein or under applicable federal and state securities laws; and when the Warrant
Stock is issued upon exercise and in accordance with the terms hereof, and this Warrant is
converted into Warrant Stock, such securities will be, at each such issuance, validly issued and
outstanding, fully paid and nonassessable, in compliance with all applicable securities laws and
free of any liens or encumbrances except for restrictions on transfer provided for herein or under
applicable federal and state securities laws.

     6.3 Capitalization. The authorized capital stock of the Company consists of
100,000,000 shares of common stock, of which 14,909,522 were issued and outstanding on February 10,
2010. All such issued and outstanding shares have been duly authorized and validly issued and are
fully paid and nonassessable. As of the date hereof, the Company has reserved a total of 6,954,155
shares of its common stock for issuance under its 1991 Stock Option Plan, the 2003 Stock Option
Plan, the 2006 Equity Incentive Plan relating to Replidyne activity prior to the merger in February
2009, and the 2007 Equity Incentive Plan (collectively, the “Company Stock Option Plans”), of which
3,529,421 shares are reserved for issuance upon exercise of outstanding options granted under the
Company Stock Option Plans. No shares of the Company’s common stock remain available for issuance
under the Company’s 1991 Company Stock Option Plan and the Company’s 2003 Stock Option Plan and the
Company’s 2006 Equity Incentive Plan, and 210,251 shares of the Company’s common stock remain
available for issuance under the Company’s 2007 Equity Incentive Plan. Except as specified in this
Warrant (including as set forth in Schedule B), there are no other options, warrants, conversion privileges or other
contractual rights presently outstanding to purchase or otherwise acquire any authorized but
unissued shares of the Company’s capital stock or other securities.

10

 

Schedule B hereto sets forth a capitalization table of the Company which is true, correct
accurate and complete as of the date hereof.

     6.4 No Conflict. The execution and delivery of this Warrant do not, and the consummation of
the transactions contemplated hereby and thereby will not, conflict with, or result in any
violation of, or default (with or without notice or lapse of time, or both), or give rise to a
right of termination, cancellation or acceleration of any obligation or to a loss of a material
benefit, under, any provision of the Restated Certificate of Incorporation or Bylaws, as amended,
or any mortgage, indenture, lease or other agreement or instrument, permit, concession, franchise,
license, judgment, order, decree, statute, law, ordinance, rule or regulation applicable to the
Company, its properties or assets, the effect of which would have a material adverse effect on the
Company or materially impair or restrict its power to perform its obligations as contemplated
hereby.

     6.5 Governmental and other Consents. No consent, approval, order or authorization of, or
registration, qualification, designation, declaration or filing with, any governmental authority or
other person or entity is required on the part of the Company in connection with the issuance, sale
and delivery of the Warrant and the Warrant Stock, except such filings as shall have been made
prior to and shall be effective on and as of the date hereof. All stockholder consents required in
connection with issuance of the Warrant and Warrant Stock have either been obtained by Borrower or
no such consents are required.

     6.6 Authorized and Unissued Shares of Common Stock. During the period within which this
Warrant may be exercised, the Company will at all times have authorized and reserved, for the
purpose of issue or transfer upon exercise of this Warrant, a sufficient number of authorized but
unissued shares of Common Stock when and as required to provide for the exercise of the rights
represented hereby.

     6.7 Exempt from Registration. Assuming the accuracy of the representations and warranties
of Holder in Section 7 hereof, the offer, sale and issuance of the Warrant and the Warrant Stock
will be exempt from the registration requirements of the Securities Act pursuant to 506 of
Regulation D under the Securities Act and from the registration and qualification requirements of
applicable state securities laws. Neither the Company nor any agent on its behalf has solicited or
will solicit any offers to sell or has offered to sell or will offer to sell all or any part of
Securities to any person or persons so as to bring the sale of such Shares by the Company within
the registration provisions of the Securities Act.

     6.8 Reporting Obligations. Borrower is and will remain subject to the reporting
requirements of Section 13 or 15(d) of the Exchange Act and (i) has filed and will file all
required reports under Section 13 or 15(d) of the Exchange Act, as applicable, during the 12 months
preceding the initial issuance of any Notes, other than Form 8-K reports; and (ii) has submitted
and will submit electronically and posted on its corporate Web site, if
any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of
Regulation S-T, during the 12 months preceding such sale (a “Reporting

11

 

Issuer”). Without limiting the foregoing, if the Company ceases to timely file periodic reports
under the Exchange Act, the Company shall from time to time promptly provide a copy of its most
recent annual, quarterly and other interim reports to Holder.

     6.9 Quotation on NASDAQ. The Warrant Stock issuable upon exchange of this Warrant has been
authorized for quotation on the Nasdaq Global Market. Any filings required by such market,
including, without limitation, the Financial Industry Regulatory Authority (“FINRA”) shall be
timely made and any required authorizations or approvals for the consummation of the transactions
contemplated herein, including, without limitation, the issuance of the Warrant Stock, have been
obtained.

     6.10 Non-Public Information. The Company shall not at any time provide PFG any material
nonpublic information, unless pursuant to Special Request (as defined in the Loan and Security
Agreement of even date herewith) and will publicly disclose the terms of this Agreement on Form 8-K
under the Exchange Act (including it as an exhibit thereto if it deems it required under applicable
law) promptly following the date hereof.

     6.11
Delivery of Information; Accuracy. The Company acknowledges its delivery of certain
Representations and Warranties dated April 14, 2010 (the “Representation Letter”), to Holder, which
Representations and Warranties form the basis for Holder purchasing the Warrant. The information
contained in Part B of the Representation Letter and all documents, instruments and other
information delivered to Holder in connection therewith are true, correct, accurate and complete in
all material respects.

     6.12 Legends. The Company shall remove any restrictive securities legends on Warrant Stock
resulting from exchange of the Warrant six (6) months following the issuance of the Warrant.

     6.13 Piggyback Registration Rights. Holder acknowledges that the Company is party to that
certain Registration Rights Agreement dated as of March 16, 2009 among the Company and certain
holders of its Common Stock. The Company shall use its best efforts to procure for the benefit of
Holder the registration rights set forth in Section 5 hereof.

Section 7. Representations and Warranties of Holder. Holder hereby represents and warrants to the
Company as of the Closing Date as follows:

     7.1 Investment Experience. Holder is an “accredited investor” within the meaning of Rule
501 under the Securities Act, and was not organized for the specific purpose of acquiring the
Securities. Holder is aware of the Company’s business affairs and financial condition and has
acquired sufficient information about the Company to reach an informed and knowledgeable decision
to acquire the Securities. Holder has such business and financial experience as is required to give
it the capacity to protect its own interests in connection with the purchase of the Securities.

     7.2 Investment Intent. Holder is purchasing the Warrant for investment for its own account
only and not with a view to, or for resale in connection with, any

12

 

“distribution” thereof within the meaning of the Securities Act. Holder understands that the
Warrant has not been registered under the Securities Act or registered or qualified under any state
securities law in reliance on specific exemptions therefrom, which exemptions may depend upon,
among other things, the bona fide nature of Holder’s investment intent as expressed herein.

     7.3 Authorization. Holder has all requisite power and has taken all
requisite action
required of it to carry out and perform all of its obligations hereunder. The execution and
delivery of this Warrant has been duly authorized, executed and delivered on behalf of Holder and
constitutes the valid and binding agreement of Holder, enforceable in accordance with its terms,
except (i) as limited by applicable bankruptcy, insolvency, reorganization or similar laws relating
to or affecting the enforcement of creditors’ rights generally and (ii) as limited by equitable
principles generally. The consummation of the transactions contemplated herein and the fulfillment
of the terms herein will not result in a breach of any of the terms or provisions of Holder’s
constitutional documents or instruments.

Section 8. Restrictive Stock Legend.

     This Warrant and the Warrant Stock have not been registered under any securities laws. Accordingly,
any share certificates issued pursuant to the exchange of this Warrant shall (until receipt of an
opinion of counsel in customary form that such legend is no longer necessary) bear the following
legend:

THIS WARRANT AND THE WARRANT STOCK ISSUABLE UPON EXCHANGE HEREOF HAVE NOT BEEN REGISTERED UNDER
THE SECURITIES ACT OF 1933 (THE “ACT”), AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR
IN CONNECTION WITH, THE SALE OF DISTRIBUTION THEREOF. NO SUCH SALE OR DISTRIBUTION MAY BE EFFECTED
WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL IN
CUSTOMARY FORM THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE ACT.

Section 9. Notices.

     Any notice or other communication required or permitted to be given here
shall be in writing and
shall be effective (a) upon hand delivery or delivery by e-mail or facsimile at the address or
number designated below (if delivered on a business day during normal business hours where such
notice is to be received) or the first business day following such delivery (if delivered other
than on a business day during normal business hours where such notice is to be received), or (b) on
the third business day following the date of mailing by express courier service, fully prepaid,
addressed to such address, or upon
actual receipt of such mailing, whichever shall first occur. The addresses for such communication
shall be:

13

 

     if to Holder, at

Partners for Growth III, L.P.

180 Pacific Avenue

San Francisco, California 94111

Attention: Chief Financial Officer

Fax: (415) 781-0510

Email: lorraine@pfgrowth.com

     with a copy (not constituting notice) to

Greenspan Law Office

Attn: Benjamin Greenspan, Esq.

620 Laguna Road

Mill Valley, CA 94941

Fax: (415) 738-5371

Email: ben@greenspan-law.com

or

     if to the Company, at

Cardiovascular Systems, Inc.

651 Campus Drive

St. Paul, MN 55112

Attn: Larry Betterley

Fax: (651) 259-1696

Email: lbetterley@csi360.com

     with a copy (not constituting notice) to:

Fredrikson & Byron

200 6th Street South

Minneapolis, MN 55402

Attn: Bert Ranum

Fax: (612) 492-7077

Email: rranum@fredlaw.com

Each party hereto may from time to time change its address for notices under this Section 7 by
giving at least 10 calendar days’ notice of such changes address to the other party hereto.

Section 10. Amendments and Waivers.

     This Warrant and any term hereof may be changed, waived, discharged or
terminated only by an instrument in writing signed by the party against which

14

 

enforcement of such change, waiver, discharge or termination is sought. This Warrant may only be
amended by an instrument in writing signed by both parties.

Section 11. Applicable Law; Severability.

     This Warrant shall be governed by and construed and enforced in accordance with
the laws of the
State of Delaware. If any one or more of the provisions contained in this Warrant, or any
application of any provision thereof, shall be invalid, illegal, or unenforceable in any respect,
the validity, legality and enforceability of the remaining provisions contained herein and all
other applications of any provision thereof shall not in any way be affected or impaired thereby.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

15

 

     IN WITNESS WHEREOF, the Company has caused this Warrant to be duly
executed on the day and year
first above written.

	 	 	 	 	 	 	 	 	 	 	 

	COMPANY:	 	 	 	 	 	ACKNOWLEDGED AND AGREED:	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	CARDIOVASCULAR SYSTEMS, INC,.	 	 	 	HOLDER:	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	Partners for Growth III, L.P.	 	 
	By:

	 	/s/ Laurence L. Betterley
 

	 	 	 	 	 	 	 	 
	 

	 	Name: Laurence L. Betterley
	 	 	 	By:	 	/s/
Lorraine Nield 	 	 
	 

	 	 

	 	 
	 	 
	 	 

	 	 
	 

	 	Title: CFO
 

	 	  
	 	 
	 	Lorraine Nield,Manager of
Partners for Growth III, LLC, 

Its General Partner	 	 

Warrant Signature Page

 

 

Exhibit A

To:

ELECTION TO EXCHANGE OR EXERCISE

1. The undersigned hereby exercises its right to exchange its Warrant for
                          
               fully paid,
validly issued and nonassessable Shares covered by the attached Warrant in accordance with the terms thereof.

1. The undersigned hereby elects to exercise the attached Warrant for fully paid, validly issued and
nonassessable Shares by payment of $                    
 as specified in the attached Warrant. This right is exercised
with respect to                      of shares.

     [Strike the paragraph above that does not apply.]

The undersigned requests that certificates for such shares be issued in the name of, and delivered to:

	 	 	 	 	 

	 
	 

	 	 

	 	 
	 
	 	 	 	 
	 

	 	 

	 	 
	 
	 	 	 	 
	 

	 	 

	 	 

2. By its execution below and for the benefit of the Company, the undersigned hereby restates each of the
representations and warranties in Section 4 of the Warrant Purchase Agreement as of the date hereof.

	 	 	 	 	 
	Date: ____________________________	[Holder]	 
	 	 	 
	 	 	 
	 	By  	
 	 
	 	 	Name:  	 	 
	 	 	Title:  	 	 

 

 

Exhibit B

ASSIGNMENT FORM

To:

     The undersigned hereby assigns and transfers this Warrant to

	 	 	 
	 	 	 
	 

(Insert assignee’s social security or tax identification number)

	 	 

 

(Print or type assignee’s name, address and postal code)

 

 

and irrevocably appoints              
                            
                   
to transfer
this Warrant on the books of the
Company.

Date:                  
                       

Partners for Growth III, L.P.

	 	 	 	 	 
	 	 	 
	 	By 	
 	 
	 	  	
 	 
	 	 	Name:  	                    , Manager of 	 
	 	 	Partners for Growth III, LLC, Its General Partner

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00173-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00173-of-00352.parquet"}]]